Monday, October 10, 2016

Why HSAN-IV? How HSAN-IV?

Congenital Insensitivity to Pain with Anhidrosis (CIPA) which is also known as HSAN-IV, is resulted by a gene mutation which happens in the human neurotrophic tyrosine kinase receptor gene, in short, the NTRK1. This gene serves to provide instructions for protein syntheses in the NTKR family. The NTKR family makes up receptors that can be found on the surface of nerve cells. These receptors respond to nerve growth factor (NGF), which is essential for proper functioning and survival of nerve cells.

            In this case, NTKR1 receptor in people with CIPA is abnormal and cannot identify NGF. This results in the nerves’ inability to survive or proper functioning. Thus, people diagnosed with CIPA are unable to feel pain or heat and also trouble with sweating.




 As CIPA is an inherited recessive genetic disorder, one copy of the faulty NTKR1 gene from each parent must be passed down to the offspring to develop this disease. If only one faulty gene is inherited, the individual is known as a “carrier” of the disease and possesses the possibility to pass down the mutation to their children. For instance, if one parent is a carrier, then his or her child will possess a 50% chance of becoming a carrier, whereas if both parents are carriers, each child will possess a 50% chance of becoming a carrier, 25% of either developing the disease or free from the disease respectively. In another word, about one out of four children may have CIPA if both the parents are carriers. Just like any other recessive disorders, there is a higher chance of developing CIPA in families that are closely related which also means they share similar blood line (“Congenital insensitivity to pain with anhidrosis”, 2011). 




Reference:
Natural Standard Research Collaboration. (2011). Congenital insensitivity to pain with anhidrosis. Natural Standard Research Collaboration. Retrieved October 10, 2016 from http://www.livingnaturally.com/ns/DisplayMonograph.asp?StoreID=3ED1FF6A18BD42979FFF73C8E8CD4512&DocID=condition-cipa





No comments:

Post a Comment